How much funding has Apogee Therapeutics raised?

Apogee Therapeutics has raised $169.0M in total funding, most recently a Series B round.

Who are Apogee Therapeutics's investors?

Apogee Therapeutics's investors include Deep Track Capital, RTW Investments.

When was Apogee Therapeutics founded?

Apogee Therapeutics was founded in 2022.

Where is Apogee Therapeutics headquartered?

Apogee Therapeutics is headquartered in South San Francisco, California, United States.

What industry is Apogee Therapeutics in?

Apogee Therapeutics operates in Biotech, Healthcare.

How many employees does Apogee Therapeutics have?

Apogee Therapeutics has 51-200 employees.

Apogee Therapeutics

IPO

Best-in-Class Therapies for Immunological and Inflammatory Disorders

Public · South San Francisco, United States · Founded 2022 · $169.0M raised

Biotech

Healthcare

Headquarters: South San Francisco, California
Employees: 51–200
Founded: 2022
Business Model: B2B
Website: apogeetherapeutics.com

Total Funding: $169.0M
Last Round: $149.0M Series BDec 2022
Rounds: 2
Type: Public

About

Apogee Therapeutics is a clinical-stage biotechnology company developing novel antibody therapeutics for inflammatory and immune diseases, including atopic dermatitis, asthma, and eosinophilic esophagitis. Founded 2022 and headquartered in South San Francisco, the company's lead program zumilokibart (APG777) targets IL-13 and is in Phase 2 trials.

Summary

Apogee Therapeutics is a Biotech company based in South San Francisco, United States, founded in 2022. It has raised $169.0M in total across 2 rounds, most recently a $149.0M Series B round in Dec 2022. Investors include Deep Track Capital and RTW Investments.